After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Moderna Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Moderna Inc is $21.10B. A total of 4.76 million shares were traded on the day, compared to an average of 5.15M shares.
In the most recent transaction, Mock James M sold 715 shares of MRNA for 60.12 per share on Oct 07 ’24. After the transaction, the Chief Financial Officer now owns 9,505 company shares. In a previous transaction on Sep 09 ’24, Klinger Shannon Thyme sold 551 shares at 73.57 per share. MRNA shares that Chief Legal Officer owns now total 18,154.
Among the insiders who bought shares, Klinger Shannon Thyme acquired of 551 shares on Sep 09 ’24 at a per-share price of $73.57. In another insider transaction, Klinger Shannon Thyme sold 114 shares at $76.99 per share on Sep 03 ’24. Company shares held by the Chief Legal Officer now total 17,566.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, MRNA has a high of $170.47 and a low of $52.26.
As of this writing, MRNA has an earnings estimate of -$1.9 per share for the current quarter. EPS was calculated based on a consensus of 16.0 estimates, with a high estimate of -$1.33 per share and a lower estimate of -$2.58. The company reported an EPS of -$9.53 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. MRNA’s latest balance sheet shows that the firm has $10.73B in Cash & Short Term Investments as of fiscal 2021. There were $916.00M in debt and $9.13B in liabilities at the time. Its Book Value Per Share was $30.50, while its Total Shareholder’s Equity was $14.14B.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MRNA is Buy with a score of 3.35.
